P
Phylo
Biotech & Life Sciences · South San Francisco, United States · Founded 2025
AI-powered integrated environment for biomedical research workflows MoreLess
Phylo is an applied AI research lab developing an Integrated Biology Environment (IBE) to unify and accelerate scientific discovery for biologists. The company was founded by Dr. Kexin Huang and Dr. Yuanhao (Jerry) Qu, who both recently earned PhDs from Stanford University. Huang's background is in computer science, focusing on AI for biomedical discovery with experience at Genentech and Pfizer, while Qu's expertise is in genetics, pathology, and CRISPR gene editing.
The company's core product, Biomni Lab, is a unified, agentic AI platform designed to address the fragmented nature of biological research. Scientists often spend significant time toggling between disparate software tools, databases, and analysis packages, which creates workflow inefficiencies. Biomni Lab acts as an orchestration layer, providing a central workspace with a chat-like interface where researchers can use natural language to execute complex tasks such as planning experiments, analyzing data, searching literature, and visualizing results like 3D molecular models. The platform integrates with hundreds of specialized tools and databases, using AI agents to automate data formatting and movement between them, significantly reducing manual work.
Phylo spun out of an open-source research project called Biomni that began at Stanford in June 2024. The project gained significant traction, being adopted by thousands of organizations, including major pharmaceutical companies. In early 2026, Phylo announced a $13.5 million seed funding round co-led by Andreessen Horowitz and Menlo Ventures' Anthology Fund to develop its commercial offering. The business model operates on a freemium basis; the core Biomni Lab is available as a free cloud service with usage limits, while a paid enterprise version offers dedicated infrastructure, custom agents, and enhanced security for larger organizations.
Keywords: Integrated Biology Environment, agentic AI, biomedical research, computational biology, workflow automation, scientific discovery, bioinformatics, AI for science, life sciences, drug discovery, data analysis, research platform, foundation models, multi-agent architecture, natural language commands, genetic engineering, molecular modeling, lab automation, pharma tech, biotech
Company overview
Phylo company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2025
- Headquarters
- South San Francisco, United States
- Employees
- 21
- Open positions
- 5
- Dealroom signal
- 88.5
Valuation & funding
Phylo funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Feb 2026 | $14M | $54M | Anthology Fund · Andreessen Horowitz | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 21 |
Growth signals
Phylo website traffic
Latest recorded traffic for Phylo is 300K monthly website visits, up 150% over the last three months.
Hiring
Open positions at Phylo
Current openings linked to this company in Dealroom.
Comparisons
Phylo compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Proxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation |
New York City, United States | Operational | 77 | $80M | $320M |
Coefficient bioAI models and agentic platforms for biopharma. |
New York City, United States | Acquired | |||
CellTypeAgentic drug discovery simulating human biology |
San Francisco, United States | Operational | |||
10x ScienceAI-native platform for next-generation protein characterization |
San Francisco, United States | Operational | |||
BoltzAI foundation models for computational drug discovery |
London, United Kingdom | Operational | |||
HotHouse TherapeuticsAI-driven plant bioengineering for therapeutic molecule discovery |
Norwich, United Kingdom | Operational | |||
Scripta TherapeuticsAI-driven drug discovery modulating transcription factor activity |
Oxford, United Kingdom | Operational | |||
ScienceMachineAutonomous AI agent for biotech data analysis |
New Castle, United States | Operational |
Talent graph
Phylo's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Phylo has talent and traffic
team presence
In the news
Latest news about Phylo
Recent press, funding announcements, and product moves mentioning Phylo — open to read from the original sources.
Market sentiment
What the market is saying about Phylo
An AI-synthesized read of the highest-engagement posts about Phylo on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Phylo’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









